Effects of Glioblastoma-derived Extracellular Vesicles on the Functions of Immune Cells

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2023 Mar 24

PMID 36960410

Authors

Oxana E Musatova

Yury P Rubtsov

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is the most aggressive variant of glioma, the tumor of glial origin which accounts for 80% of brain tumors. Glioblastoma is characterized by astoundingly poor prognosis for patients; a combination of surgery, chemo- and radiotherapy used for clinical treatment of glioblastoma almost inevitably results in rapid relapse and development of more aggressive and therapy resistant tumor. Recently, it was demonstrated that extracellular vesicles produced by glioblastoma (GBM-EVs) during apoptotic cell death can bind to surrounding cells and change their phenotype to more aggressive. GBM-EVs participate also in establishment of immune suppressive microenvironment that protects glioblastoma from antigen-specific recognition and killing by T cells. In this review, we collected present data concerning characterization of GBM-EVs and study of their effects on different populations of the immune cells (T cells, macrophages, dendritic cells, myeloid-derived suppressor cells). We aimed at critical analysis of experimental evidence in order to conclude whether glioblastoma-derived extracellular vesicles are a major factor in immune evasion of this deadly tumor. We summarized data concerning potential use of GBM-EVs for non-invasive diagnostics of glioblastoma. Finally, the applicability of approaches aimed at blocking of GBM-EVs production or their fusion with target cells for treatment of glioblastoma was analyzed.

Citing Articles

Extracellular Vesicles from Plasma of Patients with Glioblastoma Promote Invasion of Glioblastoma Cells Even After Tumor Resection.

Lyukmanova E, Kirichenko A, Medyanik I, Yashin K, Kirpichnikov M, Bychkov M Biomedicines. 2025; 12(12.

PMID: 39767739 PMC: 11673896. DOI: 10.3390/biomedicines12122834.

Glioma-Derived Exosomes and Their Application as Drug Nanoparticles.

Mastantuono S, Manini I, Di Loreto C, Beltrami A, Vindigni M, Cesselli D Int J Mol Sci. 2024; 25(23).

PMID: 39684236 PMC: 11641060. DOI: 10.3390/ijms252312524.

Tackling Anticancer Drug Resistance and Endosomal Escape in Aggressive Brain Tumors Using Bioelectronics.

Jain A, Wade P, Stolnik S, Hume A, Kerr I, Coyle B ACS Omega. 2024; 9(42):42923-42931.

PMID: 39464448 PMC: 11500143. DOI: 10.1021/acsomega.4c05794.

Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance.

Tataranu L, Turliuc S, Kamel A, Rizea R, Dricu A, Staicu G Curr Issues Mol Biol. 2024; 46(9):9881-9894.

PMID: 39329940 PMC: 11430601. DOI: 10.3390/cimb46090588.

MicroRNA-enriched exosome as dazzling dancer between cancer and immune cells.

Hsu C, Ahmed A, Bansal P, Hjazi A, Al-Hetty H, Qasim M J Physiol Biochem. 2024; 80(4):811-829.

PMID: 39316240 DOI: 10.1007/s13105-024-01050-x.

References

Soeda A, Hara A, Kunisada T, Yoshimura S, Iwama T, Park D . The evidence of glioblastoma heterogeneity. Sci Rep. 2015; 5:7979. PMC: 4306917. DOI: 10.1038/srep07979. View

Xu X, Liu Y, Li Y, Chen H, Zhang Y, Liu J . Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway. J Exp Clin Cancer Res. 2021; 40(1):16. PMC: 7789663. DOI: 10.1186/s13046-020-01810-9. View

Kennedy B, Maier L, DAmico R, Mandigo C, Fontana E, Waziri A . Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol. 2009; 10:11. PMC: 2654428. DOI: 10.1186/1471-2172-10-11. View

Sento S, Sasabe E, Yamamoto T . Application of a Persistent Heparin Treatment Inhibits the Malignant Potential of Oral Squamous Carcinoma Cells Induced by Tumor Cell-Derived Exosomes. PLoS One. 2016; 11(2):e0148454. PMC: 4743844. DOI: 10.1371/journal.pone.0148454. View

Wang X, Cao Q, Shi Y, Wu X, Mi Y, Liu K . Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFRα pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: Functional validation and clinical theranostic significance. Int J Biol Sci. 2021; 17(4):1061-1078. PMC: 8040305. DOI: 10.7150/ijbs.57168. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Thakur A, Xu C, Li W, Qiu G, He B, Ng S . In vivo liquid biopsy for glioblastoma malignancy by the AFM and LSPR based sensing of exosomal CD44 and CD133 in a mouse model. Biosens Bioelectron. 2021; 191:113476. DOI: 10.1016/j.bios.2021.113476. View

Takov K, Yellon D, Davidson S . Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential. J Extracell Vesicles. 2019; 8(1):1560809. PMC: 6327926. DOI: 10.1080/20013078.2018.1560809. View

Thakur A, Qiu G, Xu C, Han X, Yang T, Ng S . Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma. Sci Adv. 2020; 6(26):eaaz6119. PMC: 7319757. DOI: 10.1126/sciadv.aaz6119. View

10.

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

11.

Naryzhny S, Volnitskiy A, Kopylov A, Zorina E, Kamyshinsky R, Bairamukov V . Proteome of Glioblastoma-Derived Exosomes as a Source of Biomarkers. Biomedicines. 2020; 8(7). PMC: 7399833. DOI: 10.3390/biomedicines8070216. View

12.

de Vrij J, Maas S, Kwappenberg K, Schnoor R, Kleijn A, Dekker L . Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 2015; 137(7):1630-42. DOI: 10.1002/ijc.29521. View

13.

Ridder K, Keller S, Dams M, Rupp A, Schlaudraff J, Del Turco D . Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol. 2014; 12(6):e1001874. PMC: 4043485. DOI: 10.1371/journal.pbio.1001874. View

14.

Strauss S, Meng A, Ebani E, Chiang G . Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. Neuroimaging Clin N Am. 2020; 31(1):103-120. DOI: 10.1016/j.nic.2020.09.010. View

15.

Harshyne L, Hooper K, Andrews E, Nasca B, Kenyon L, Andrews D . Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm. Cancer Immunol Immunother. 2014; 64(3):299-309. PMC: 11029437. DOI: 10.1007/s00262-014-1622-z. View

16.

Perrin G, Schnuriger V, Quiquerez A, Saas P, Pannetier C, Tribolet N . Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol. 1999; 11(8):1337-50. DOI: 10.1093/intimm/11.8.1337. View

17.

Noerholm M, Balaj L, Limperg T, Salehi A, Zhu L, Hochberg F . RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012; 12:22. PMC: 3329625. DOI: 10.1186/1471-2407-12-22. View

18.

Dusoswa S, Horrevorts S, Ambrosini M, Kalay H, Paauw N, Nieuwland R . Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells. J Extracell Vesicles. 2019; 8(1):1648995. PMC: 6713149. DOI: 10.1080/20013078.2019.1648995. View

19.

Bavaresco L, Bernardi A, Braganhol E, Cappellari A, Rockenbach L, Fernandes Farias P . The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem. 2008; 319(1-2):61-8. DOI: 10.1007/s11010-008-9877-3. View

20.

Husain N, Chiocca E, Rainov N, Louis D, Zervas N . Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 1998; 95(3):287-90. DOI: 10.1007/s004010050799. View